
RANI Stock Forecast & Price Target
RANI Analyst Ratings
Bulls say
Rani Therapeutics Holdings Inc has demonstrated the capability of its RaniPill technology to deliver biologics orally, achieving comparable biological activity and enhanced bioavailability, with RT-114 showing a relative bioavailability of approximately 111% compared to subcutaneous dosing. The partnership with Chugai provides additional validation from a significant industry player and positions Rani to capitalize on the expanding market for oral obesity therapies, highlighted by strong M&A activity in 2026. Additionally, the company is well-capitalized with a cash runway extending through 2028, allowing for continued investment in the advancement of its technologies without compromising its financial stability.
Bears say
Rani Therapeutics Holdings Inc faces significant challenges that contribute to a negative outlook on its stock, primarily linked to uncertainties in its revenue forecasts and market competition. The company's reliance on achieving assumed reimbursement levels is critical, and any failure to meet these assumptions could adversely impact financial projections. Additionally, while the safety profile of the RaniPill platform is deemed promising, concerns regarding the potential for clinical trial failures and the modest valuation ascribed to the platform indicate that the market may not fully recognize the associated risks and the current undervaluation of these assets.
This aggregate rating is based on analysts' research of Rani Therapeutics Holdings and is not a guaranteed prediction by Public.com or investment advice.
RANI Analyst Forecast & Price Prediction
Start investing in RANI
Order type
Buy in
Order amount
Est. shares
0 shares